Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study

Langley, Joanne M.; MacDougall, Donna; Halperin, Donna; Swain, Ann; Halperin, Scott A.; Top, Karina A; McNeil, Shelly; MacKinnon‐Cameron, Donna; Marty, Kim; Serres, Gaston De; Dubé, Ève; Bettinger, Julie A.

doi:10.1016/j.vaccine.2016.06.025

Cited by 22 publications

(11 citation statements)

References 11 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 15 Comparison of the adverse effects reported by the parents showed that the children in group B significantly more frequently experienced pain with functional impotence and pain at the inoculation site, whereas those in group A more frequently experienced mild general reactions such as restlessness, fever, headache and diarrhea. These findings are in line with those of many studies of MenB 21 , 28 , 29 and other vaccinations 30-32 and indicate that the onset of adverse events is age related. No serious side effects were reported.…”

Section: Discussionsupporting

confidence: 91%

Spontanuous Demand For Meningococcal B Vaccination: Effects On Appropriateness And Timing

Giuliani

Mattei

Appetiti

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

When the meningococcus B vaccine was introduced into Italy in 2017, it was recommended for newborns based on national epidemiological data indicating that they were at greater risk. However, the vaccination service of the local health authority of L'Aquila had already been receiving spontaneous parental requests to provide vaccination for children in lower-risk age groups from the beginning of 2016. We therefore decided to use a self-administered questionnaire in order to investigate the parents’ socio-demographic data; their children's history of other recommended vaccinations (against measles, mumps and rubella, varicella, meningococcus C and, for females, human papilloma virus); the information sources concerning meningococcal vaccination; and the timing of its administration.The questionnaire was completed by 565 parents, and the results showed that the requests mainly came from the parents of children aged 5–11 years. The children whose mothers had received a high school education and were >35 years old were more likely to have received the first dose after the age of one year and to have perceived pain at the inoculation site, and less likely to have experienced mild general reactions. The requests were mainly trigged by the recommendations of healthcare professionals, and the overloading of the vaccination service led to delays in the administration of the doses after the first. The delays (reported by 74.07% of the parents) were mainly due to organisational problems in the service itself, which led 61.52% of the doses being more appropriately administered by staff working as private physicians inside public health facilities, albeit at extra cost.These findings indicate that organisational factors and excessive demand had a considerable impact on both the efficacy of the immunisation and its appropriateness.

show abstract

Section: Discussionsupporting

confidence: 91%

Spontanuous Demand For Meningococcal B Vaccination: Effects On Appropriateness And Timing

Giuliani

Mattei

Appetiti

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“… Proof of concept that app to demonstrate technology is functional Wilson 39 Canada 2016 5155 Yes Pregnant women SMS 84.3% replied by SMS Day 7 after vaccination TIV and dTpa High response rate Review of both antenatal vaccines. AEFI data collection by SMS differs to other methods – further investigation required Safety data supports antenatal vaccination Regan 35 Australia 2016 987 Yes University students and staff Email with link to online survey 33% 8–10 days after each dose Meningococcal B vaccine - 4CMenB Support of emergency vaccine programme Emergency response so full methodology previously developed unable to be employed Medically attended events more frequent than in clinical trial data but local reactions consistent with previously reported Langley 33 Canada …”

Section: Resultsmentioning

confidence: 97%

“… 32 The Canadian system was also able to adapt rapidly and be deployed for AEFI surveillance of meningococcal B vaccine (4CMenB, Bexsero) during a meningococcal B outbreak in university students. 33 …”

Section: Resultsmentioning

confidence: 99%

Participant-centred active surveillance of adverse events following immunisation: a narrative review

Cashman

Macartney

Khandaker

et al. 2017

International Health

View full text Add to dashboard Cite

The importance of active, participant-centred monitoring of adverse events following immunisation (AEFI) is increasingly recognised as a valuable adjunct to traditional passive AEFI surveillance. The databases OVID Medline and OVID Embase were searched to identify all published articles referring to AEFI. Only studies which sought participant response after vaccination were included. A total of 6060 articles published since the year 2000 were identified. After the application of screening inclusion and exclusion criteria, 25 articles describing 23 post-marketing AEFI systems were identified. Most countries had a single system: Ghana, Japan, China, Korea, Netherlands, Singapore, Brazil, Cambodia, Sri Lanka, Turkey and Cameroon except the USA (2), Canada (4) and Australia (6). Data were collected from participants with and without AEFI in all studies reviewed with denominator data enabling AEFI rate calculations. All studies considered either a single vaccine or specified vaccines or were time limited except one Australian system, which provides continuous automated participant-centred active surveillance of all vaccines. Post-marketing surveillance systems using solicited patient feedback are emerging as a novel AEFI monitoring tool. A number of exploratory systems utilising e-technology have been developed and their potential for scaling up and application in low and middle income countries deserves further investigation.

show abstract

“…IMD is endemic in Canada and the majority of cases are caused by serogroup B (MnB) (National Advisory Committee on Immunization 2014; Li et al 2014), including the recent outbreak in Nova Scotia, as well as the prolonged increased incidence in the province of Quebec (De Wals et al 2017;Langley et al 2016;Nova Scotia Department of Health and Wellness 2015). Serogroup B meningococcus was responsible for 63% of all IMD cases in Canada between 2011 and 2015 (Public Health Agency of Canada 2017).…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada

Breton

Huang

Snedecor

et al. 2020

Can J Public Health

View full text Add to dashboard Cite

Objective Serogroup B meningococci (MnB) are now the largest cause of invasive meningococcal disease (IMD) in Canada. We assessed the clinical and economic impact of 3 adolescent MenB-FHbp immunization strategies. Methods A population-based dynamic transmission model was developed to simulate the transmission of MnB among the entire Canadian population over a 30-year time horizon. Age group-based IMD incidence, bacterial carriage and transmission, disease outcomes, costs, and impact on quality of life were obtained from Canadian surveillance data and published literature. The vaccine was assumed to provide 85% protection against IMD and 26.6% against carriage acquisition. The model estimated the impact of routine vaccination with MenB-FHbp in 3 strategies: (1) age 14, along with existing school-based programs, with 75% uptake; (2) age 17 with 75% uptake, assuming school vaccination; and (3) age 17 with 30% uptake, assuming vaccination outside of school. Costs were calculated from the Canadian societal perspective. Results With no vaccination, an estimated 3974 MnB cases would be expected over 30 years. Vaccination with strategies 1-3 were estimated to avert 688, 1033, and 575 cases, respectively. These outcomes were associated with incremental costs per quality-adjusted life-year of $976,000, $685,000, and $490,000.Conclusions Our model indicated that if the vaccine reduces risk of carriage acquisition, vaccination of older adolescents, even at lower uptake, could have a significant public health impact. Due to low disease incidence, MnB vaccination is unlikely to meet widely accepted cost-effectiveness thresholds, but evaluations of new programs should consider the overall benefits of the vaccination. en milieu scolaire, à un taux de vaccination de 75 %; (2) immunisation à l'âge de 17 ans, en milieu scolaire, à un taux de vaccination de 75 %; et (3) immunisation à l'âge de 17 ans, à un taux de vaccination de 30 %, en contexte extrascolaire. Les coûts ont été calculés en fonction de la perspective sociétale canadienne. Résultats Sans immunisation, le nombre estimé de cas de méningococcie du sérogroupe B serait de 3974 sur une période de 30 ans. Selon le modèle, les stratégies de vaccination 1 à 3 préviendraient respectivement 688, 1033 et 575 cas. Ces résultats ont été associés à des coûts différentiels par année de vie gagnée ajustée par la qualité (QALY) de 976 000 $, 685 000 $ et 490 000 $. Conclusions Le modèle utilisé dans le cadre de l'analyse a permis d'indiquer que si le vaccin réduisait le risque d'acquisition du portage, la vaccination des adolescents plus vieux, même en présence de taux de vaccination plus faibles, pouvait avoir des répercussions significatives sur la santé publique. En raison de la faible incidence de la maladie, il est peu probable que la vaccination contre le MnB respecte les seuils généralement acceptés en matière de coût-efficacité, mais l'évaluation de nouveaux programmes devrait tenir compte de l'ensemble des bienfaits associés à la vaccination.

show abstract

Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study

Cited by 22 publications

References 11 publications

Spontanuous Demand For Meningococcal B Vaccination: Effects On Appropriateness And Timing

Spontanuous Demand For Meningococcal B Vaccination: Effects On Appropriateness And Timing

Participant-centred active surveillance of adverse events following immunisation: a narrative review

Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada

Contact Info

Product

Resources

About